JP2016501520A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501520A5
JP2016501520A5 JP2015543449A JP2015543449A JP2016501520A5 JP 2016501520 A5 JP2016501520 A5 JP 2016501520A5 JP 2015543449 A JP2015543449 A JP 2015543449A JP 2015543449 A JP2015543449 A JP 2015543449A JP 2016501520 A5 JP2016501520 A5 JP 2016501520A5
Authority
JP
Japan
Prior art keywords
substituted
alkynyl
alkenyl
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015543449A
Other languages
English (en)
Japanese (ja)
Other versions
JP6463687B2 (ja
JP2016501520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/074552 external-priority patent/WO2014080004A1/en
Publication of JP2016501520A publication Critical patent/JP2016501520A/ja
Publication of JP2016501520A5 publication Critical patent/JP2016501520A5/ja
Application granted granted Critical
Publication of JP6463687B2 publication Critical patent/JP6463687B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015543449A 2012-11-26 2013-11-25 Fgfr3の発現の調節のための組成物及び方法 Expired - Fee Related JP6463687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261729922P 2012-11-26 2012-11-26
US61/729,922 2012-11-26
PCT/EP2013/074552 WO2014080004A1 (en) 2012-11-26 2013-11-25 Compositions and methods for modulation of fgfr3 expression

Publications (3)

Publication Number Publication Date
JP2016501520A JP2016501520A (ja) 2016-01-21
JP2016501520A5 true JP2016501520A5 (OSRAM) 2016-12-01
JP6463687B2 JP6463687B2 (ja) 2019-02-06

Family

ID=49639882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015543449A Expired - Fee Related JP6463687B2 (ja) 2012-11-26 2013-11-25 Fgfr3の発現の調節のための組成物及び方法

Country Status (11)

Country Link
US (1) US9725723B2 (OSRAM)
EP (1) EP2922955B1 (OSRAM)
JP (1) JP6463687B2 (OSRAM)
KR (1) KR20150088305A (OSRAM)
CN (1) CN104903448B (OSRAM)
BR (1) BR112015012051A2 (OSRAM)
CA (1) CA2889993A1 (OSRAM)
DK (1) DK2922955T3 (OSRAM)
MX (1) MX2015006289A (OSRAM)
RU (1) RU2015120645A (OSRAM)
WO (1) WO2014080004A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
EP3521451A1 (en) 2010-11-17 2019-08-07 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
ES2862073T3 (es) 2012-07-13 2021-10-06 Wave Life Sciences Ltd Grupo auxiliar asimétrico
CN112007045A (zh) 2012-07-13 2020-12-01 波涛生命科学有限公司 手性控制
WO2014080004A1 (en) 2012-11-26 2014-05-30 Santaris Pharma A/S Compositions and methods for modulation of fgfr3 expression
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
RU2759746C1 (ru) 2018-03-19 2021-11-17 Тайхо Фармасьютикал Ко., Лтд. Фармацевтическая композиция, включающая алкилсульфат натрия
EP4098263A4 (en) * 2020-01-31 2024-03-20 Kyoto University TREATMENT FOR CHONDRODYSTROPHY
JPWO2022211095A1 (OSRAM) * 2021-03-31 2022-10-06

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
AU776362B2 (en) 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
EP2957568B1 (en) 2002-11-05 2016-12-21 Ionis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
DK2284269T3 (en) 2002-11-18 2017-10-23 Roche Innovation Ct Copenhagen As Antisense design
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2007061127A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
EP1984381B1 (en) 2006-01-27 2010-09-29 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007131237A2 (en) 2006-05-05 2007-11-15 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of ptp1b
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
BRPI0716823A2 (pt) 2006-09-15 2015-05-26 Enzon Pharmaceuticals Inc Conjunto poliméricos contendo porções positivamente carregadas
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
EP2090127A2 (en) 2006-10-30 2009-08-19 Nokia Corporation Method, apparatus and system providing operator controlled mobility for user equipment
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
WO2009090182A1 (en) * 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
AT507215B1 (de) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg Verschleissbeständiger werkstoff
PE20120553A1 (es) * 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
WO2011139843A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Multi-sirna compositions for reducing gene expression
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
WO2014080004A1 (en) 2012-11-26 2014-05-30 Santaris Pharma A/S Compositions and methods for modulation of fgfr3 expression
US9778708B1 (en) 2016-07-18 2017-10-03 Lenovo Enterprise Solutions (Singapore) Pte. Ltd. Dual sided latching retainer for computer modules

Similar Documents

Publication Publication Date Title
JP2016501520A5 (OSRAM)
JP2016503300A5 (OSRAM)
JP2013508347A5 (OSRAM)
JP2015042636A5 (ja) 有機化合物
JP2017119663A5 (OSRAM)
JP2015181191A5 (OSRAM)
JP2013102146A5 (ja) 化合物
JP2016521119A5 (OSRAM)
JP2013521295A5 (OSRAM)
JP2010254680A5 (ja) 複素環化合物、及び発光素子
JP2014526533A5 (OSRAM)
JP2012528196A5 (OSRAM)
JP2010254679A5 (ja) トリアゾール誘導体、発光素子、及び発光装置
JP2011016798A5 (OSRAM)
JP2010254681A5 (ja) 複素環化合物、及び発光素子
JP2014508179A5 (OSRAM)
JP2018531301A5 (OSRAM)
JP2011079866A5 (OSRAM)
JP2015083560A5 (ja) 有機金属錯体
JP2014101364A5 (OSRAM)
JP2019507133A5 (OSRAM)
JP2015044793A5 (ja) 有機化合物
JP2011079832A5 (OSRAM)
JP2015044795A5 (ja) トリフルオロフェニル誘導体
CN302267676S (zh) 发电机后罩(1)